$ABVX If you read the reddit boards (I know I know), they're is a consistent theme amongst N. American or Western Euros UC and CD patients saying their doctor offered them a chance to enroll in an Obe trial, but they opted for another drug because of how burdensome a trial can be (extra scopes, regular monitoring, even requiring wearing a condom during sex). Additionally, they were all worried that they would be put on the placebo, which would inevitably delay effective treatment. Whenever there is a question of "what should I do" all the other redditors say they should take the approved drug and not risk getting the placebo. Logically, there are fewer of these concerns in less-developed countries, where participants will happily try a free treatment AND get paid for it.
ABTECT-1 and ABTECT-2 site distributions. does it skew a bit Hispanic/Eastern Euro and poor? maybe. welcome to clinical trials brother. God forbid a nigga get a little IBD after eating too many burritos and pierogis
$ABVX
2
24
1,579
$ABVX Another doozy of a disclaimer that I haven't seen others mention yet. Quite literally, we need to "consider the source" of all the disgruntled employee shit-talking:
"We believe the experts we spoke with are reliable sources of information with respect to ABVX. However, we cannot and do not provide any representations or warranties with respect to the accuracy of the information they have provided to us. The quotations of experts used in this article do not reflect all information they have shared with us, including, without limitation, certain positive comments and experiences with respect to ABVX. In addition, the experts have typically received compensation for their conversations with us and may have conflicts of interest or other biases with respect to ABVX, which may give them an incentive to provide us with inaccurate, incomplete or otherwise prejudiced information. The former employees of ABVX that we spoke with are by definition separated from the company and thus the information they have provided may be outdated.All experts agreed, both in writing and orally, to not provide any material non-public information or any information that they are obligated to keep confidential, and that their service as a consultant or their participation in our research calls does not violate any confidentiality agreement or other obligation they have with their employer or any person or entity. The quotations of experts used in this article are based on Scorpion Capital LLC conversations with such experts and may be paraphrased, truncated, and/or summarized solely at our discretion, and do not always represent a precise transcript of those conversations."
$ABVX ha you've got to be kidding me. The lawyers have made them give up the game:
7
868
Contrast these examples with $SLS today. In particular, $ABVX doing a data dump in their maintenance PR crushed them. Should have just provided headline maintenance remission numbers and verbatim wrote what SLS wrote: "GPS (Obe) was generally well tolerated, with a safety profile consistent with prior clinical experience and no new safety signals identified."
Instead they literally put section dedicated to f'ing CANCER (!) in the release, and left the market to wonder for themselves what that meant. Infuriating.
$ABVX $HELP $IONS OK I have to vent a bit. I don't understand how a biotech company can navigate first-in-human clinical trials and yet completely blunder the easiest part: communicating the data effectively in a press release.
You usually have one asset and/or one indication that matters. You have hundreds of millions, sometimes billions, of dollars of cash. You have an investor base with which you are in constant communication. You have sell side analysts who are constantly talking to you and asking you questions from investors that provide you some reference point on what matters to them. You also have an understanding of how your global and site PI have been thinking about the risk/benefit of the product. You also have the benefit of the FDA's communications as well.
You have 3-5 major data updates throughout your lifecycle as a company, from topline data, to updated data, to initial guidance and call on the drug launch, if you aren't acquired before then. These milestones materially impact how the world views the value of your highly speculative asset and company. This asset may have been in development for a decade or more. You've run a clinical trial burning hundreds of millions of dollars of cash to generate the data that proves to the world all of that blood, sweat and tears along the way was worth it and you are one of the few companies that have successfully developed a product that could be a massive commercial success.
And then you dump a steaming hot mess of a press release onto the market right before you plan to raise money. All that time and energy that went into ensuring the trial worked just got partially, or permanently, impaired because no one stepped back and determined what are the most important questions and concerns that an investor would be wondering about, and to address those questions immediately when they are reading the press release to ensure they aren't smashing the sell button before you have a chance to address them. At least halt the stock, that's why that functionality exists.
Let's talk about a few recent ones, starting with the most recent (today): $HELP. Ok, you have fantastic efficacy. That's great. And along the way, you have some SAEs. That's ok, lots of drugs have SAEs, and they will be weighed against your great efficacy. Even better, your SAE's look like they may actually just be manifestation of the underlying symptoms of the disease (i.e. depression and suicidal ideation). So who in the world thought it was a good idea to identify these SAEs as treatment-related, then leave it to the reader's imagination on the nature of these SAEs while the stock was unhalted???
Are these patients even still alive? You could have not disclosed them in the PR and disclosed all the detail in the presentation, and have been fine. You could have disclosed them in the PR and provided detail to help investors understand that these weren't catastrophic in nature. And yet you willingly did neither. And now you've created new narrative overhangs that have emerged in order to explain the share price movement even after it is disclosed the SAEs were not only common with this indication, but were one of the primary symptom manifestations of the underlying disease.
I have shorts over here that will try to hide Grade 5 liver toxicity events by not disclosing them and claiming they hadn't yet ruled out that the late 39 y.o. former physician didn't take up wild mushroom eating during his time on the trial, and yet longs will just throw out "oh yeah, there were a few serious drug-induced events but we aren't disclosing what they are...usually a bad sign right?? Just wait until we reveal to you what these things are...did they make our efficacy completely irrelevant?? Take a guess!" and then later on give details that made me question why in the world they would not have given that detail earlier before people obliterated their share price.
$IONS was another great example. sHTG was the only thing that really mattered this recent earnings. Their initial guide earlier this year was bizarrely high, then they guide down and provide no useful metrics to immediately understand that the launch is actually doing ok. Instead, we get a Rubik's Cube of select random datapoints that I have to make assumptions around to back into what the launch looks like, only to realize they've now completely swung the pendulum in the other direction and guided to a number that makes it seem to anyone looking at it at surface level like they're not going to get another incremental patient on drug in 4Q, rather just run-rate their prior quarter in patients. Every other company gives start forms, why am I having to back into projecting what I think are decent enough revs based on a mix of lives covered, % of physicians who prescribed drug to more than one patient, net pricing, assumptions on prior indication growth, and percentage of physicians who ate ham sandwiches while placing an order for the drug in their EMR?
$ABVX We've beaten this dead horse enough. But the list wouldn't be credible if it didn't exist on it.
I have offered to go under CDA and restrict myself to help companies I own to provide feedback on how to effectively communicate press release data, but the number of companies who take me up on it are quite small. Worse over, I know of instances where top holders will consult with the company in such a matter, and yet the PR is still a mess.
If your company is a 10% position in my fund, I'm going to care a LOT about how that press release is written, even if notionally I'm less than a large fund's holdings. If you are a .5% to 2% position, the incentive to really dig in and think about all ways that communication could fail is much smaller than mine.
Please stop screwing up the easiest part of drug development -- the promotion of your own asset, and relying on people to figure it out on their own. You'll find that in an era of increasingly short term horizon investors, the mistake may have more permanent consequences than ever before. And then pharma looks at the share price movement, reads the same PR, and comes to the same wrong conclusion about the reality of the situation.
2
19
2,050
$ABVX interesting question from Mr. Mike Hunt. $ABVX will be at the LifeSci X Sofinnova conference. The latter name likely being the answer to the question. It is a very targeted conference for late stage investors. Also, Tokat from Centerview is taking the mainstage on a topic that should interest everyone. Kinam Hong was also the abvx board member when Sofinnova had a seat earlier this year. Ipsen (chairmen MdG) also on stage. So, while $ABVX doesn't have a formal presentation or fireside chat at Jefferies, I am certain they will do this Lifesci-Sofinnova conference on Monday, have individual meetings there, and have any number of meetings lined up during the week while everyone is in town for Jefferies. The conference spaces are a 10 minute walk from each other. For what it's worth, Helikon (currently amassing a large position in Abivax) is also nearby the conference sites.
4
30
4,921
From $ABVX 20-F, independent analysis says $21.8 billion in UC in the US alone in 2032. As Adam says, 50% penetration estimate from the KOL is extremely aggressive, but one can dream...
Completely incorrect. $3.2B in 2032 in US alone is *20%* penetration by their “own number”. That’s also the number that Morgan Stanley incorrectly claimed they were calling “peak sales”. Completely incorrect there too.
50% penetration in US alone by 2032 (per projections) would be $7.5B, not $3.75B as you claim.
Worldwide adds several billion $ more on top of that.
Check slide 5 of their corporate deck. You’re giving the wrong numbers.
Bioadvo retweeted
💊 Obefazimod holds the line in UC.
📍 ABTECT-Maintenance (phase 3, #UEGWeek2026): 580 induction responders re-randomised for 44 more weeks
🎯 Clinical remission at week 52: 51% on 25 mg AND 50 mg vs 10% placebo
🔬 Endoscopic remission 41–48% vs 10%. Both doses beat placebo on all 8 key endpoints (p<0.0001)
🔁 Works after advanced-therapy failure too: 34–42% vs 7% remission
⚠️ Any AE 50% / 58% / 72%; 2 non-skin cancers on 50 mg, judged unlikely related
👇 The full maintenance data in one image
🔗 ir.abivax.com/news-releases/…
@my_ueg
#MedTwitter #GITwitter #MedEd #IBD #UlcerativeColitis #Obefazimod
$ABVX I was doing some Chat research and discovered that $ABVX published a new patent application in August 2026. Anyone talk about this yet? They are attempting to cover specific dosing schedules (25 mg and 50 mg) in maintenance treatment. Chat tells me that, if granted, the patent could provide protection through 2044. Chat also told me that competitors/generics could design around the dosing claims and gave a bunch of other caveats - it's far from a done deal. I have very little knowledge of patent law and this could just be abivax throwing things against the wall and seeing what sticks. Apparently, Abbvie has a similar dosing patent for Rinvoq (45mg induction then 15mg maintenance) that was granted.
Anyone who knows more than me able to opine?
patents.google.com/patent/US…
$ABVX The $LLY Gastro X account continues to post things that seemingly tee-up the use case for Obefazimod. 63% lower risk of relapse if patients achieve clinical + endo + histologic remission. Well, why not get all of that in one safe pill per day?
Even in endoscopic remission, patients with UC face a 14% annual risk of relapse.¹,† Underlying histologic inflammation can exist despite endoscopic healing, increasing relapse risk.² How are you deciding when endoscopic remission isn't enough?
1
17
1,204
$ABVX "IT WORKS"
Obefazimod in UC: the phase 3 maintenance data, from two talks @my_ueg
580 people with moderate to severe ulcerative colitis who responded to 8 weeks of obefazimod, a once-daily oral medicine, were re-randomised for 44 more weeks. Placebo here meant stopping a drug that had just worked.
It works. Clinical remission at week 52 was 39 percentage points higher than placebo on 25 mg and 40 points higher on 50 mg.
It works across the secondary endpoints too. On endoscopic improvement, endoscopic remission (Mayo 0), histo-endoscopic mucosal improvement, steroid-free remission, sustained remission, clinical response and symptomatic remission, the delta over placebo ran from 31 to 53 points, every one at p<0.0001.
It works with and without prior advanced-therapy (AT) failure. In AT-naive patients the delta in clinical remission was 45-48%; after AT failure it was 28-33%; smaller, but still large.
And it was well tolerated. Serious adverse events were within 2 points of placebo on either dose, fewer people stopped for an adverse event on drug than on placebo, and there were no deaths. Two cancers outside the skin, both on 50 mg, were judged unlikely to be related.
What next: @Abivax_ plans to file in the US by the end of 2026, and the full phase 3 paper(s) are still to come. The first Crohn's data, from the phase 2b ENHANCE-CD trial, are due in mid-2027.
$ABVX $SNY $TEVA Interestingly, the Poster from the 2025 UEGW presentation DID include Endoscopic Remission. Curious why they didn't include it this year, isn't it???
Smarter people than me can do a better job of comparing these results to Obe, but at induction Obe 50mg had an 18% PBO delta in MES 2 and a 10% delta in MES 3 patients. Superior to Duva.
Now consider Obe was 8 weeks and Deva was 14 weeks. Given what we know about Obe's response deepening, it's not a far leap to assume Obe's Endo Remission at 14 weeks are far stronger at week 14 (and beyond, of course).
Also, let's not forget potential Duva side effects are worse than Obe, in Teva's own words: "The most frequent observed adverse events (≥5% of all patients) with pooled duvakitug doses were upper respiratory tract infection, nasopharyngitis, Crohn’s disease, and hypertension and were consistent with the RELIEVE UCCD phase 2b induction study."
$SNY $TEVA original Duvakitug (TL1A) maintenance data PR from February didn't give endoscopic data.
The updated PR from their #UEGW presentation today *does* give endoscopic improvement numbers...but not endoscopic remission??? The most important endpoint?
Hey! Their OPEN LABEL P2 maintenance endoscopic improvement rates are *lower* than $ABVX Obe's 50mg BLINDED P3 endoscopic improvement rates...
...and they aren't even giving us the endoscopic remission data? Unless they were given at the conference but for some reason kept out of the press release?
Another $ABVX W?
1
28
2,421
🎣 A first-in-class oral for UC with ~40-point placebo-adjusted remission at week 44?
🧵 Obefazimod heads to #UEGWeek2026 (Barcelona, 17–20 Oct) with 7 abstracts, incl. full ABTECT-Maintenance data.
Topline wk44 clinical remission: 51% (25 mg) & 51% (50 mg) vs 10% placebo. Endoscopic remission up to 48%.
A new mechanism (miR-124 ↑) — where does it fit vs JAKi & S1P? 👇
#IBD #UlcerativeColitis #GastroTwitter #ClinicalResearch
13
1,694
We're on the ground at #UEGWeek2026!
Visit us at booth 32 to learn more about Abivax and the potential of obefazimod for the treatment of #InflammatoryBowelDisease.
We hope to see you there.
534






























